Saturday 17 October 2026
Export MDGL’s income statement to Excel — free account
Madrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024. In the quarter to June 2026, revenue grew 71.2%, EPS fell 32.9%, free cash flow grew 140.5% and total debt rose 187.9%, each against the same quarter a year earlier.
449.74
10.07
−2.19%
Follow MDGL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(41.22%) | (42.49%) | (49.35%) | (53.31%) | |
| (23.74%) | (25.05%) | (27.83%) | (28.77%) | ||
ROIC |
0.00% | 0.00% | (297.52%) | (787.33%) | |
Return on Tangible Assets |
(30.17%) | (30.77%) | (36.32%) | (38.86%) | |
Average Days of Receivables |
55.83 | 51.21 | 60.38 | 54.67 | |
Free Cash Flow per Share |
(7.36) | (8.65) | (9.39) | (7.08) | |
Free Cash Flow |
(165.54) | (193.99) | (272.61) | (206.28) | |
Capital Expenditures |
(4.96) | (4.44) | (4.51) | (8.57) | |
| Other line items | |||||
Cash ROIC |
(7.96%) | (10.05%) | (16.02%) | (12.11%) | |
Accounts Receivable Turnover |
10.30 | 10.18 | 9.10 | 9.46 | |
Accounts Payable Turnover |
0.77 | 1.21 | 1.53 | 3.02 | |
Inventory Turnover |
0.90 | 1.03 | 0.94 | 1.34 | |
Average Days of Payables |
466.74 | 317.74 | 282.77 | 115.13 | |
Days of Inventory on Hand |
719.89 | 486.52 | 521.21 | 331.53 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
40.22% | 40.54% | 40.00% | 38.17% | |
Selling, General and Administrative Expense of Revenue |
96.55% | 84.91% | 80.75% | 78.43% | |
Share Based Compensation of Revenue |
12.15% | 10.24% | 9.82% | 9.46% | |
Interest Coverage |
(17.56) | (13.45) | (11.68) | (10.24) | |
Operating CF/Net income |
0.56 | 0.66 | 0.87 | 0.61 | |
Depreciation/Fixed assets |
1.65 | 4.22 | 0.83 | 0.64 | |
Capex/Depreciation |
(1.03) | (0.70) | (0.67) | (1.16) | |
Revenue per Share |
32.94 | 42.72 | 39.01 | 44.05 | |
Operating CF per Share |
(7.14) | (8.45) | (9.23) | (6.78) | |
Capex per Share |
(0.22) | (0.20) | (0.16) | (0.29) | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.01 |
Columns are period end dates